Results 101 to 110 of about 40,773 (330)

Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer

Breast Cancer Research, 2022
Background Preclinical and epidemiological studies indicate a potential chemopreventive role of low-density lipoprotein cholesterol (LDL-C) -lowering drugs in the risks of breast cancer and prostate cancer, but the causality remains unclear.
Lulu Sun, H. Ding, Yiming Jia, Mengyao Shi, D. Guo, Pinni Yang, Yu Wang, Fanghua Liu, Yonghong Zhang, Zhengbao Zhu   +9 more
semanticscholar   +1 more source

Regulation of PCSK9 by nutraceuticals

Pharmacological Research, 2017
PCSK9 (proprotein convertase subtilisin kexin type 9) is a liver secretory enzyme that regulates plasma low-density lipoprotein (LDL) cholesterol (LDL-C) levels through modulation of LDL receptor (LDLR) density on the surface of hepatocytes. Inhibition of PCSK9 using monoclonal antibodies can efficiently lower plasma LDL-C, non-high-density lipoprotein
Matteo Pirro, Amirhossein Sahebkar, Amirhossein Sahebkar, Niki Katsiki, Maciej Banach, Amir Abbas Momtazi   +5 more
openaire   +4 more sources

Association of circulating proprotein convertase subtilisin/kexin type 9 concentration, prothrombin time and cardiovascular outcomes: a prospective cohort study

Thrombosis Journal, 2021
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) is considered to have multiple roles in the development of atherosclerosis, which is recently reported to participate in the thrombotic process. We aimed to examine the relationship between
Jia Peng, Ming-Ming Liu, Hui-Hui Liu, Yuan-Lin Guo, Na-Qiong Wu, Qian Dong, Jie Qian, Ke-Fei Dou, Cheng-Gang Zhu, Jian-Jun Li   +9 more
doaj   +1 more source

Association of Serum Anti-PCSK9 Antibody Levels with Favorable Postoperative Prognosis in Esophageal Cancer

Frontiers in Oncology, 2021
BackgroundEsophageal cancer often appears as postoperative metastasis or recurrence after radical surgery. Although we had previously reported that serum programmed cell death ligand 1 (PD-L1) level correlated with the prognosis of esophageal cancer ...
Masaaki Ito, Takaki Hiwasa, Takaki Hiwasa, Yoko Oshima, Satoshi Yajima, Takashi Suzuki, Tatsuki Nanami, Makoto Sumazaki, Fumiaki Shiratori, Kimihiko Funahashi, Shu-Yang Li, Yasuo Iwadate, Hiroki Yamagata, Byambasteren Jambaljav, Minoru Takemoto, Minoru Takemoto, Koutaro Yokote, Hirotaka Takizawa, Hideaki Shimada, Hideaki Shimada   +19 more
doaj   +1 more source

Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling

Protein & Cell, 2021
Metabolic regulation has been proven to play a critical role in T cell antitumor immunity. However, cholesterol metabolism as a key component of this regulation remains largely unexplored. Herein, we found that the low-density lipoprotein receptor (LDLR),
Juanjuan Yuan, Ting Cai, Xiaojun Zheng, Yangzi Ren, Jing Qi, Xiaofei Lu, Huihui Chen, Huizhen Lin, Zijie Chen, Mengnan Liu, Shangwen He, Qijun Chen, Siyang Feng, Yingjun Wu, Zhenhai Zhang, Yanqing Ding, Wei Yang   +16 more
semanticscholar   +1 more source

PCSK9 Inhibitors

Cell, 2016
Alirocumab and evolocumab are monoclonal antibodies that block proprotein convertase subtilisin/kexin type 9 (PCSK9), a circulating protein that degrades low-density lipoprotein (LDL) receptors. These therapies increase LDL receptors on the cell surface and reduce plasma LDL cholesterol. Both therapies are approved to lower LDL cholesterol, a causative
Sekar Kathiresan, Pradeep Natarajan
openaire   +3 more sources

PCSK9 is minimally associated with HDL but impairs the anti-atherosclerotic HDL effects on endothelial cell activation

Journal of Lipid Research, 2022
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) regulates the cell-surface localization of LDL receptors in hepatocytes and is associated with LDL and lipoprotein(a) [Lp(a)] uptake, reducing blood concentrations.
Ioannis Dafnis, Aikaterini N. Tsouka, Christina Gkolfinopoulou, Constantinos C. Tellis, Angeliki Chroni, Alexandros D. Tselepis   +5 more
doaj  

The E3 ubiquitin ligase c-IAP1 regulates PCSK9-mediated LDLR degradation: Linking the TNF-α pathway to cholesterol uptake [PDF]

, 2010
Proprotein convertase subtilisin/kexin type 9 (PCSK9), in addition to LDLR (low-density lipoprotein receptor) and APOB (apolipoprotein B), is one of three loci implicated in autosomal dominant hypercholesterolaemia (ADH)^1^.
Lizhi Liu, Weiming Xu
core   +1 more source

PCSK9 is expressed in human visceral adipose tissue and regulated by insulin and cardiac natriuretic peptides [PDF]

, 2019
open8noProprotein convertase subtilisin/kexin type 9 (PCSK9) binds to and degrades the low-density lipoprotein receptor (LDLR), contributing to hypercholesterolemia.

core   +1 more source

Research Models for Studying Vascular Calcification [PDF]

, 2020
Calcification of the vessel wall contributes to high cardiovascular morbidity and mortality. Vascular calcification (VC) is a systemic disease with multifaceted contributing and inhibiting factors in an actively regulated process.
Babic, Milen, Giet, Markus van der, Herrmann, Jaqueline, Schuchardt, Mirjam, Tölle, Markus   +4 more
core   +1 more source